Natco Pharma has launched Brivaracetam tablets under brand Brecita in India. Brivaracetam is indicated towards treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact. Natco’s Brecita tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of Rs 25 and Rs 35 per tablet respectively.
Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
